Leland Metheny
Clinical trials sponsored by Leland Metheny, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Antibody-Drug combo tested to stop leukemia from returning after transplant Results expected Nov 2026 (estimated)
- Gene-Edited stem cells may let doctors use stronger chemo against brain cancer Results expected Nov 2026 (estimated)
-
Gene-Edited stem cells may let doctors use stronger chemo against brain cancer
Disease control Recruiting nowThis study tests a new approach for people with a recently removed glioblastoma (a fast-growing brain tumor). Doctors take some of the patient's own blood stem cells, add a protective gene (P140K MGMT) to them, and return them to the patient. This allows the use of higher doses o…
Phase 2 • Sponsor: Leland Metheny • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Antibody-Drug combo tested to stop leukemia from returning after transplant
Prevention Recruiting nowResearchers are testing inotuzumab ozogamicin, an antibody-drug conjugate, in people with CD22-positive acute lymphocytic leukemia who have already had a stem cell transplant. The trial has two parts: a phase 1 portion to find the highest dose that is safe to give after transplan…
Phase 1/2 • Sponsor: Leland Metheny • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC